REVELATION BIOSCIENCES, INC. Credit Risk Derivative Liabilities, at Fair Value
REVELATION BIOSCIENCES, INC. (REVB) had Credit Risk Derivative Liabilities, at Fair Value of $1.01 million as of 2021-12-31, per its 10-K filed 2022-04-15.
Discontinued › Notes
us-gaap:CreditRiskDerivativeLiabilitiesAtFairValue · last filed 2022-04-15
- 2021-12-31: Credit Risk Derivative Liabilities, at Fair Value $1.01M.
| Period end | Credit Risk Derivative Liabilities, at Fair Value |
|---|---|
| 2021-12-31 | $1.01M 10-K · filed 2022-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |